Equulus Therapeutics
Preclinical2 active candidates
same indication: PTSDPreclinical peersame regulator: US FDAsimilar active pipeline size
Back to StakeholdersProgramme tracker View landscape
Lead program: Preclinical
Tactogen
CategoriesEarly-Stage Translational Research (Pre-Clinical)Research, Drug Development & Manufacturing
Data updated
3 Drug Candidates
Enterprise Intelligence
Quarterly psychedelic drug-development briefing
Compare indication activity, programme milestones, competitive intensity, and near-term catalysts. Q2 includes quarter-over-quarter changes against the published Q1 baseline.
Tactogen is a Palo Alto-based public benefit corporation developing novel MDMA-like entactogens and psychedelic-adjacent molecules for psychiatric disorders. Founded in 2020 by neuroscientist Matthew Baggott and Luke Pustejovsky, Tactogen has built the largest known library of entactogenic compounds. Lead candidate TACT908 is a non-hallucinogenic 5-HT1B/2A agonist for cluster headache, while TACT833 targets alcohol use disorder and eating disorders. Following the 2024 FDA rejection of Lykos's MDMA, Tactogen has pivoted toward its novel NCE pipeline.
Pipeline Intelligence
Developer Momentum
- Active candidates
- 2
- Active programmes
- 2
- Lead stage
- Preclinical
- Forecast coverage
- 2 of 2
3 total in tracker
3 total in tracker
Current furthest stage
2 active programmes with forecast fields
Latest sourced update
Tactogen Pipeline
Jun 26, 2026 - company-website - Tactogen - TACT908 (2ZEDMA)
Next known catalyst
preclinical-data
Timing not specified - Novel Entactogen Library (TACT833/411/523) / Novel Benzofuran Entactogen Library Preclinical Programme - Confidence: 25%
5 sources0 pipeline-linked trials0 pipeline-linked papers
Development Programmes
3TACT908 (2ZEDMA)
Preclinical
Cluster headache
Headache Disorders (Cluster & Migraine)
Primary: US (FDA)
Pre-clinicalActive
TACT908 remains a preclinical cluster-headache programme, supported by Tactogen pipeline/patent material and drug-database tracking.
Milestones
Pre-clinical completed
In progressWhy it matters: TACT908 (2ZEDMA) is a benzofuran-based serotonin receptor agonist (5-HT1B/5-HT2A) designed for cluster headache without producing hallucinations. Cluster headache patients often report sub-hallucinogenic doses of psychedelics abort attacks — TACT908 is designed to replicate this mechanism without the psychedelic experience, enabling non-supervised use.
Watch next: IND-enabling data and Phase 1 FIH timeline announcement
Evidence Links
Tactogen Pipeline
company-website - Tactogen - Jun 26, 2026 - Verified
Company pipeline page supports Tactogen development of novel small molecules for mental-health and neurological contexts.
Tactogen Drug Pipeline Profile
drug-database - PatSnap Synapse - Jun 26, 2026 - Verified
Drug database profile lists TACT-908 as a preclinical cluster-headache programme.
Cluster Headache Market Developments - TACT908
industry-media - BioSpace / Coherent Market Insights - Jan 1, 2025 - Verified
Market-development summary lists TACT908 as a preclinical serotonin-receptor agonist for cluster headache.
MDMA + Citalopram Combination
PreclinicalPaused
PTSD
PTSD
Primary: US (FDA)
Pre-clinicalpaused
Phase 2 in planning (was targeted 2025); under strategic review following FDA rejection of Lykos MDMA-AT (August 2024); possible deprioritisation in favour of novel proprietary compounds
Milestones
Regulatory review accepted
PlannedLikely: Q3 2026
No public source found confirming completed regulatory acceptance for MDMA+citalopram in August 2024. Public sources support a paused/planned programme under strategic review after Lykos FDA rejection.
Why it matters: The Lykos rejection created regulatory uncertainty for all MDMA-based PTSD therapies. Tactogen's MDMA+citalopram combination (where citalopram attenuates the subjective MDMA "high") was positioned to address the FDA's therapy-component criticism, but the broader regulatory climate post-Lykos makes any MDMA PTSD programme more challenging.
Watch next: Tactogen announcement or registry entry confirming MDMA+citalopram IND clearance, Phase 2 launch, or formal deprioritisation.
Evidence Links
Tactogen pipeline page emphasizes current discovery/IP platform rather than active MDMA+citalopram clinical start
company-website - Tactogen - Jun 27, 2026 - Verified
Company pipeline page reviewed June 27, 2026; current page describes broader candidate discovery, IP, and collaborations, without confirming a completed MDMA+citalopram regulatory acceptance milestone.
MDMA developers reprioritize following Lykos FDA rejection
industry-media - BioSpace - Sep 30, 2024 - Verified
Secondary coverage describes the post-Lykos MDMA regulatory setback context and Tactogen reprioritization considerations.
Novel Entactogen Library (TACT833/411/523)
Preclinical
PTSD / alcohol use disorder
PTSD
Primary: US (FDA)
Pre-clinicalActive
Forecast
preclinical-data
TACT833/411/523 remains a preclinical Tactogen entactogen programme. Public evidence is mostly undated company pipeline language, older patent applications, and drug-database tracking; no fresh trial, IND, financing, or candidate-selection update was found in the June 2026 sweep. Keep as waiting-on-news.
Milestones
Pre-clinical completed
In progressWhy it matters: Tactogen's benzofuran entactogens are structurally derived from 5-MAPB (a widely studied MDMA-like benzofuran) but with optimised selectivity to reduce neurotoxicity, cardiovascular risk, and abuse potential. Preliminary Phase 1 data comparing 5-MAPB to MDMA showed equivalent reductions in social anxiety and improvements in self-compassion, validating the benzofuran pharmacology.
Watch next: Lead compound selection from TACT833/411/523 series and IND-enabling timeline
Evidence Links
Tactogen Pipeline
company-website - Tactogen - Jun 26, 2026 - Verified
Company pipeline page says Tactogen is evaluating novel small molecules and had filed more than a dozen patent applications as of mid-2025; the page itself is undated.
Justia Tactogen benzofuran and aminoindane patent applications
patent - Justia Patents - May 18, 2023 - Verified
Justia lists Tactogen patent applications including benzofuran compositions published 2023-05-18 and 2-aminoindane compounds published 2023-06-15.
TACT411/833 Drug Profile
drug-database - PatSnap Synapse - Jun 26, 2026 - Verified
Drug profile lists TACT411/833 as preclinical for AUD, anorexia, and binge-eating disorder.
Similar Developers
Reference points selected from shared pipeline stage, indications, compounds, regulatory pathways, and evidence footprint.
PharmAla Biotech
Preclinical2 active candidates
same indication: PTSDPreclinical peersame regulator: US FDAsimilar active pipeline size
Remedi Therapeutics
Preclinical2 active candidates
same indication: PTSDPreclinical peersame regulator: US FDAsimilar active pipeline size
Silo Pharma
Preclinical2 active candidates
same indication: PTSDPreclinical peersame regulator: US FDAsimilar active pipeline size
Quick Facts
- Type
- Public Benefit Corporation
- Founded
- 2020
- Lead Stage
- Preclinical
- Website
- Visit